HIMS is trading 5.4% up today at $36.55 after Canaccord raised its price target to $40 from $32, maintaining a Buy rating. Bank of America also increased its price target to $36 from $25. - The upgrades come despite earlier concerns about FDA staff questioning the safety of certain peptides. - The stock's positive movement suggests strong investor response to the analyst endorsements.